7.28.03: Biotechnology Issue
Eight analysts and top management from twenty seven sector firms examine the Biotechnology sector in this 149-page Biotechnology Issue from The Wall Street Transcript.
  1. Biotechnology - In an in-depth (9,700 words) Roundtable Forum, Jennifer M. Chao, a Senior Analyst & Managing Director at RBC Capital Markets, Michael G. King, a Managing Director & Senior Equity Research Analyst at Banc of America Securities, Eric Schmidt, a Managing Director and Senior Research Analyst at SG Cowen Securities Corp. and Thomas Shrader, a Research Analyst at Harris Nesbitt Gerard, Inc., examine the outlook for the sector and share specific stock recommendations.
  2. Small Cap Biotechnology Companies - In an in-depth (3,500 words) Analyst Interview, Russell Gilbertson, a Research Analyst at Roth Capital Partners, LLC, examines the outlook for the sector and shares specific stock recommendations.
  3. Biotechnology, Genomics & Gene Therapy - In an in-depth (4,300 words) Analyst Interview, Craig D. West, an Associate Vice President and Senior Biotech Analyst at A.G. Edwards & Sons, examines the outlook for the sector and shares specific stock recommendations.
  4. Investing in Biotechnology - In an in-depth (1,700 words) Analyst Interview, Rahul Jasuja, a Research Analyst at Techvest, LLC, examines the outlook for the sector and shares specific stock recommendations.
  5. Therapeutics-Based Companies - In an in-depth (3,600 words) Analyst Interview, Mark Schoenebaum, a Principal & Senior Research Analyst at U.S. Bancorp Piper Jaffray Inc., examines the outlook for the sector and shares specific stock recommendations.
  6. CEO interviews (average 2,500 words). Top management of twenty seven - sector firms examine the outlook for their firm and the sector. Firms include:
    Amarillo Biosciences, Applied Molecular Evolution, BioCryst Pharmaceuticals, Biomira Inc., BioSource International, Cortex Pharmaceuticals, DNAprint genomics, DOV Pharmaceutical, Embrex, Genaera Corporation, Genaissance Pharmaceuticals, GeneMax Corp., Gen-Probe Incorporated, ImmuCell Corporation, Immune Response Corporation, Implant Sciences Corporation, NeoRx Corporation, Orchid BioSciences, Ortec International, Paradigm Genetics, Peregrine Pharmaceuticals, Proterion Corporation, Provectus Pharmaceuticals, StemCells, SuperGen, Transkaryotic Therapies
    7. ORDER THIS REPORT NOW! ONLY $175
    The report will be mailed first class. For fedex delivery, specify in the report details section and either include your fedex number or we will add $15 delivery charge. All sales are final.  Questions, call (212) 952-7433, or email us
    For immediate access online - click here to gain a password.
     
    Report details:  
    Your Name:  
    		 Company: 
    Address: 
    		 City: 
    State/Province:
    		 ZIP/Postal Code:
          		 Country:
    Phone:
    		 E-Mail:

    BILLING INFORMATION
    Credit Card
    		 Expiration Month/Year:
    Credit Card Number: 
     

     This Issue costs $175 - and is non-returnable.   

    The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

     

Investors and Industry Execs.

The Wall Street Transcript has been read and used by investors and industry executives for nearly 40 years. It's a vital and unique tool for doing company and industry research - as part of a stock purchase decision or as part of a market analysis.

Investors:
TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. Find out where they agree, and where they disagree on stock recommendations. Money manager interviews provide the view from the buy-side. And CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.

Industry Executives:
Get the insider view on the sector from Wall Street Analysts and Company CEO's. Company strategies, growth ambitions, new products and markets, management - these and much more are discussed by the top executives in the industry. TWST's reports should be a key part of any industry research.

Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.

Sincerely,

Andrew Pickup
Publisher
HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE